Na Chen

Dr. Na Chen


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2024 in Chemosensors
Verified
Journal Article
Open access
PDF file
MZMingxiao Zhang
Mingxiao Zhang
MGMengjia Guo
Mengjia Guo
NCNa Chen
Na Chen
ZTZhuqian Tang
Zhuqian Tang
JXJunjie Xiang
Junjie Xiang
HLHua Li
Hua Li
Moringa oleifera leaves (MOLs) have gained significant attention due to their nutritional and biological activity. Therefore, this study aimed to examine its flavor characteristics and underlying compositions. In this study, we used ultra-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF-MS), gas chromatography-mass spectrometry (GC-MS), electronic nose, electronic tongue, and molecular docking to comprehensively investigate the chemical properties and flavor profiles of MOLs. UPLC-Q-TOF-MS and GC-MS were instrumental in identifying the 20 non-volatile and 19 volatile constituents of MOLs, respectively. The electronic nose and electronic tongue systems provided an objective evaluation of the sweet, bitter, and spicy attributes and flavor characteristics of MOLs. Concurrently, molecular docking was employed to elucidate the material basis of flavor profiles. It revealed that glucosinolates and flavonoids are probably the key components for the bitter taste of MOLs. The sweet taste may be attributed to glucosinolates and flavonoids. The spicy scent appears to be linked to the presence of glucosinolates and alkaloids. The integration of these techniques confers a thorough understanding of the chemical composition and sensory properties of MOLs. These findings have significant implications for innovative applications in the food industry as well as pharmaceuticals and agriculture sectors; furthermore, they contribute towards enhancing the perception of Moringa oleifera as a valuable natural resource.

31 October 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
DZDi Zhu
Di Zhu
DGDan Gao
Dan Gao
YLYu Lu
Yu Lu
NCNa Chen
Na Chen
LZLi Zhang
Li Zhang
Yuji WangYuji Wang
Yuji Wang
Background: Protein arginine deiminase 4 (PAD4) has emerged as a promising therapeutic target for acute promyelocytic leukemia (APL) because of its role in epigenetic regulation and leukemogenesis. All-trans retinoic acid, a standard differentiation agent in APL therapy, has been shown to upregulate PAD4 expression during leukemic cell maturation. Interestingly, first-generation PAD4 inhibitors also promote differentiation, but simultaneously trigger compensatory PAD4 overexpression, underscoring the unresolved complexity of PAD4 modulation in leukemia therapy. Methods: In this study, we employed mass cytometry and transcriptomic–proteomic integrated analysis to investigate the underlying mechanisms of YW3-56, a dual-function PAD4 inhibitor against protein expression and enzymatic function, in NB4 leukemia cells. Functional validation was conducted using Western blot and metabolic assays. Results: Mass cytometry analysis revealed that YW3-56 reduced leukemia stemness (CD44/CD133), while enhancing myeloid differentiation (CD11b/CD14) and immunogenic activation (CD80/CD86). Multiomics analysis revealed a YW3-56-induced metabolic shift characterized by downregulation of glycolytic enzymes and upregulation of the tricarboxylic acid cycle and pentose phosphate pathway components, indicating a reversal of the Warburg effect. Mechanistically, this metabolic reprogramming was driven by reduced AKT expression and phosphorylation at Thr308, impaired GLUT1 expression and membrane localization, and decreased glucose uptake, which collectively promoted the differentiation of NB4 cells. Additionally, YW3-56 suppressed the downstream mTOR pathway, inducing caspase-3/PARP-mediated apoptosis and inhibiting cell proliferation. Conclusions: Our study demonstrated that YW3-56 exerts multimodal antileukemic effects in APL by simultaneously targeting PAD4-mediated epigenetic regulation, AKT-driven metabolic reprogramming and cellular differentiation, highlighting PAD4-AKT signaling as a promising target for APL combination therapy.